title: [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
abstract: To evaluate the prognostic significance of CD7 expression in de novo acute myeloid leukemia (AML), we studied 63 patients with AML who had been admitted to our hospital between September 1989 and January 1996. Even of the patients were later eliminated from the study (9 due to insufficient surface marker analyses, and 2 due to early death). The remaining 52 patients (median age: 42.5 years) were evaluated for morphologic subtype, immunophenotypic classification, complete remission (CR), disease-free survival (DFS) and overall survival (OS). All 52 patients were grouped by the French-American-British classification system: 10 as M1, 16 as M2, 11 as M3, 8 as M4, 5 as M5, and 2 as M6. Ten of the patients expressed CD7 on their leukemia cells (positive rate > or = 25) and were classified as CD7(+)AML, with morphological subtypes as follows: 3 as M1, 6 as M2, and 1 as M3. Thirty-three of the 42 patients with CD7 + AML (78.6%) and 6 of the 10 patients with CD7 + AML (40%) achieved CR. DFS and OS rates for the patients with CD7(+)AML were 22.1% and 35.4%, respectively; those for the CD7(+)AML patients were 53.3% and 44.4%, respectively. No significant differences in gender hematological findings, clinical manifestations such as hepatosplenomegaly, lymphadenopathy, or incidence of central nervous system involvement, CR rate, and DFS distinguished patients with CD7(+)AML from those with CD7(+)AML. These suggest that CD7 expression is unlikely to be a prognostic factor in AML.
authors.affiliation: Department of Hematology/Oncology, Jikei University Hospital.
authors.forename: T
authors.initials: T
authors.lastname: Saito
authors.forename: N
authors.initials: N
authors.lastname: Usui
authors.forename: N
authors.initials: N
authors.lastname: Dobashi
authors.forename: N
authors.initials: N
authors.lastname: Maki
authors.forename: O
authors.initials: O
authors.lastname: Asai
authors.forename: S
authors.initials: S
authors.lastname: Yano
authors.forename: A
authors.initials: A
authors.lastname: Kato
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Katori
authors.forename: M
authors.initials: M
authors.lastname: Nagamine
authors.forename: A
authors.initials: A
authors.lastname: Ogihara
authors.forename: H
authors.initials: H
authors.lastname: Yamazaki
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: N
authors.initials: N
authors.lastname: Tajima
authors.forename: Y
authors.initials: Y
authors.lastname: Kuraishi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019011:Antigens, CD7 / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D019011:Antigens, CD7; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003561:Cytarabine; D014212:Tretinoin; D011239:Prednisolone; D013866:Thioguanine; D003630:Daunorubicin